Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing

Rhea-AI Summary

Made Scientific (HLTH) appointed Ted Dolan and Soyoung Park to its Board to support scale-up and commercial readiness in cell therapy manufacturing. The company said the expanded Board brings CDMO operations, commercialization, strategy, and financial expertise as it expands GMP capacity at its Princeton, NJ campus and partners with GC Corporation.

Positive

• Appointed Ted Dolan and Soyoung Park to Board
• Expanding GMP manufacturing capacity at Princeton, NJ campus
• Board experience spans CDMO operations and commercialization
• Supported by strategic shareholder GC Corporation

Negative

• None.

Market Context

This announcement detailed the build-out of a Board with deep CDMO, financial, and strategic experti...

Analysis

This announcement detailed the build-out of a Board with deep CDMO, financial, and strategic expertise to support late-phase and commercial cell therapy manufacturing. For HLTH, pre-news trading showed a price of 0.0434, at the 52-week low and well below the 0.18 200-day MA, alongside volume 387.67x the 20-day average. Investors may watch for concrete operational milestones, capacity expansion progress, and commercialization wins to validate this governance-focused positioning.

Key Figures

CDMO leadership experience: more than 40 years Board build-out period: over the past year Strategy experience: more than two decades +2 more

5 metrics

CDMO leadership experience more than 40 years Ted Dolan’s CDMO and pharma manufacturing leadership

Board build-out period over the past year Timeframe of assembling the current Board

Strategy experience more than two decades Soyoung Park’s strategy and advisory experience in bio-healthcare

Healthcare ecosystem experience more than 25 years Jin Pyun’s experience across the global healthcare ecosystem

Leadership experience over 40 years Harry S. Rathore’s pharma life sciences and CDMO leadership

Key Terms

contract development and manufacturing organization, cdmo, cell therapies, gmp manufacturing, +3 more

7 terms

contract development and manufacturing organization technical

"Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO)"

A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

cdmo technical

"a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cell therapies medical

"organization (CDMO) specializing in cell therapies, today announced the continued build-out"

Cell therapies are medical treatments that use living cells as the active medicine to repair, replace or reprogram damaged tissue or disease processes; the cells can come from the patient, a donor, or be made in a lab. For investors, they matter because they can offer long-lasting or curative effects unlike conventional drugs, but they also carry high research and manufacturing costs, complex regulation and scaling challenges—think of them as custom-built machines that can do remarkable work but are expensive and tricky to produce and deliver.

gmp manufacturing technical

"Made Scientific expands its GMP manufacturing capacity at its Princeton, NJ campus"

GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.

drug substance technical

"leadership across drug substance, drug product, and analytical services"

The drug substance is the primary active ingredient in a medicine—the chemical or biological material that produces the intended therapeutic effect. Think of it like the main ingredient in a recipe: its availability, purity, cost to make, and the ability to produce it at scale affect regulatory approvals, manufacturing reliability and profit margins, so investors watch it as a key factor in a drug’s commercial prospects and risk profile.

drug product technical

"leadership across drug substance, drug product, and analytical services"

The drug product is the finished, usable medication that reaches patients — the formulated and packaged pills, injectables, creams or liquids that contain the active ingredient plus other components needed for delivery, labeling and storage. Investors care because drug products drive actual sales, require regulatory approval and consistent manufacturing quality, and problems with production, labeling or safety can quickly affect revenue, launch timelines and company value, much like a recalled consumer product harms a brand.

biologics medical

"CDMO sector specializing in small molecules and biologics. He currently serves on several boards"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its Board of Directors, including the appointment of Ted Dolan and Soyoung Park. They join Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, alongside Chairman and CEO Syed T. Husain, as part of a deliberate effort to align the company's governance with its next phase of growth.

Over the past year, Made Scientific has assembled a Board with deep experience spanning CDMO operations, global commercialization, the broader healthcare ecosystem, strategic planning, and financial stewardship. With these additions, the Board further strengthens its ability to support the company's transition toward late-phase and commercial cell therapy manufacturing.

This evolution comes as Made Scientific expands its GMP manufacturing capacity at its Princeton, NJ campus to meet increasing demand from advanced therapy developers. As programs move closer to commercialization, the ability to scale operations, ensure operational discipline, and execute reliably becomes critical — areas where the Board brings direct, relevant experience.

Made Scientific is supported by GC Corporation, a long-term strategic shareholder providing stability, global perspective, and sustained investment in the business. This partnership reflects a shared commitment to building deliberately — prioritizing scale and quality over short-term outcomes — and positions Made Scientific to advance cell therapy manufacturing with a long-term vision.

"As both Chairman and CEO, I've been very intentional about how we've built this Board over time," said Syed T. Husain. "These are leaders who understand how to scale in complex environments and how therapies move through the broader healthcare ecosystem. With the addition of Ted and Soyoung, we are even better positioned to execute as we expand capacity, support increasingly complex and late-stage programs, and continue progressing toward becoming a leading cell therapy CDMO partner."

Board of Directors

SYED T. HUSAIN

Syed T. Husain serves as Chairman and Chief Executive Officer of Made Scientific, bringing deep experience across the CDMO spectrum from development through commercialization of established and emerging therapeutic modalities, and leading the company's evolution toward late-phase and commercial cell therapy manufacturing. He previously served as Chief Commercial Officer at Resilience, where he drove commercial growth and established strategic partnerships. Earlier in his career, he held senior leadership roles at Emergent BioSolutions, Alcami Corporation, and Lonza.

TED DOLAN

Ted Dolan brings more than 40 years of CDMO and pharmaceutical manufacturing leadership across drug substance, drug product, and analytical services. He most recently served as COO of BioVectra and has held senior leadership roles at Alcami, Lonza, and Johnson Matthey. He adds deep operational expertise in scaling manufacturing organizations and driving execution across complex programs.

YONGHOON KIM

Yonghoon Kim brings extensive experience in global investment and financial management. He currently serves as CFO of MOHABI Investment USA, Inc., with prior experience at international investment and accounting firms including PwC Korea and NH Investment & Securities (formerly Woori Investment & Securities).

SOYOUNG PARK

Soyoung Park brings more than two decades of experience in strategy and advisory within the bio-healthcare sector, including IQVIA, A.T. Kearney, and Oliver Wyman. She currently serves as Managing Director of Strategy Planning at GC Corporation. Her background strengthens Made Scientific's strategic planning capabilities and supports alignment with global partners, including long-term collaboration with GC Corporation.

JIN PYUN

Jin Pyun is CEO of GC Ventures and brings more than 25 years of experience across the global healthcare ecosystem, including biopharma, digital health, and healthcare delivery. He has held leadership roles at Pfizer, Nobilis Health (formerly, NYSE: HLTH), WebMD, and HealthTap, driving commercialization and market development strategies across both B2C and B2B healthcare platforms.

HARRY S. RATHORE, Ph.D.

Harry S. Rathore brings over 40 years of leadership experience across the pharma life sciences and CDMO sector specializing in small molecules and biologics. He currently serves on several boards, including Gannet Biochem and Ascensus Specialties and is a Founder & CEO of Symmetra Biosciences — an advisory practice dedicated to CDMO and PE clients. Previously, Harry has held chief executive roles at Borregaard Synthesis, Lonza India, Callery LLC, and Polyorganix, Inc.

About Made Scientific

Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise to deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit madescientific.com.

Media Contact

Lucy Taylor
Head of Marketing
Made Scientific, Inc.
media@madescientific.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/made-scientific-strengthens-board-to-support-scale-up-and-commercial-readiness-in-cell-therapy-manufacturing-302759103.html

SOURCE Made Scientific, Inc.

FAQ

What did Made Scientific (HLTH) announce on April 30, 2026?

Made Scientific announced new Board appointments and a capacity focus to support commercialization. According to Made Scientific, Ted Dolan and Soyoung Park joined the Board as it expands GMP manufacturing at its Princeton, NJ campus to serve late‑stage and commercial cell therapy programs.

Who are the new board members at Made Scientific (HLTH) and what are their backgrounds?

The company named Ted Dolan and Soyoung Park to the Board, adding operations and strategy expertise. According to Made Scientific, Dolan brings 40+ years in CDMO and pharmaceutical manufacturing; Park brings two decades in bio‑health strategy and GC Corporation collaboration experience.

How will the Board changes affect Made Scientific's cell therapy manufacturing scale-up (HLTH)?

The Board additions are intended to strengthen governance for late‑phase and commercial manufacturing. According to Made Scientific, the expanded Board brings direct experience in scaling operations, operational discipline, and executing complex, late‑stage cell therapy programs as capacity grows.

What role does GC Corporation play with Made Scientific (HLTH)?

GC Corporation is a long‑term strategic shareholder providing stability and global perspective. According to Made Scientific, GC offers sustained investment and strategic alignment that supports deliberate growth, prioritizing scale and quality over short‑term outcomes.

Is Made Scientific increasing GMP manufacturing capacity at its Princeton, NJ campus (HLTH)?

Yes — the company is expanding GMP manufacturing capacity at its Princeton campus to meet growing demand. According to Made Scientific, the expansion aims to support advanced therapy developers as programs approach commercialization and require larger, reliable manufacturing capability.